USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies
USC PE-GCS:优化西班牙裔结直肠癌患者参与癌症基因组特征研究
基本信息
- 批准号:10294884
- 负责人:
- 金额:$ 371.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-22 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvocateAfrican AmericanAgeAge-YearsAreaBehavioralBehavioral SciencesBiologyBiomedical ResearchCaliforniaCancer EtiologyCause of DeathCessation of lifeCharacteristicsClinicClinicalClinical DataCollaborationsColorectal CancerCommunicationCommunitiesCommunity OutreachConsentData AnalysesDiagnosisDiseaseEthnic groupEtiologyFastingFosteringGenomeGenomicsGoalsHealth Services AccessibilityHigh PrevalenceHispanicsIncidenceKnowledgeLaboratoriesLatinoLeadMalignant NeoplasmsMedicalMexicanMinorityMolecularNot Hispanic or LatinoOutcomePatient PreferencesPatient-Focused OutcomesPatientsPositioning AttributeProcessRectal CancerReportingResearchRiskScientistSubgroupTaxonomyTechniquesTechnologyTestingThe Cancer Genome AtlasTimeTreatment FactorUnderrepresented MinorityUnderserved Populationcancer carecancer genomecancer genomicscaucasian Americancolon cancer patientscommunity engagementdemographicsdesignearly onset colorectal cancergenome sequencinggenomic datahealth care settingsimprovedmembernovelnovel strategiesparticipant enrollmentpatient engagementpatient populationresearch studysocioeconomicstranslational cancer researchtranslational genomics
项目摘要
ABSTRACT
Colorectal Cancer (CRC) is the second leading cause of cancer death in the US. Hispanic/Latinos are the largest
and fasting growing ethnic group in the US, and cancer is the leading cause of death among H/L in the US.
Therefore, we need to fully understand the full complexity of the molecular etiology of cancer in this ethnic group.
For instance, although incidence rates of CRC are lower among Latinos as compared to Whites or African
Americans, Hispanics with metastatic disease have shorter overall survival when adjusted for health care setting,
demographics, disease characteristics and treatment factors. H/L also tend to be diagnosed at a younger age
and with higher stage, and we have previously reported that Mexican H/L in California have the greatest
proportion of young (<50 years of age) diagnoses compared to other H/L subgroups. Moreover, Mexican H/L
showed higher prevalence of rectal cancer cases compared to other H/L and NHW. Although socio-economics
and access to care might influence these differences, we need to take a complete look at the biology of disease
in this ethnic group to determine once and for all if these clinical differences are related to differences in molecular
etiology. The Cancer Genome Atlas has provided a deep overview of the molecular taxonomy of CRC in 594
cases, however, less than 1% of the cases (n=5) were H/L. Therefore, it is imperative for us to take more detailed
assessment of the molecular genomic landscape of CRC in H/L. One of the major issues likely limiting our ability
to perform these large genomic initiatives in minority patients is that Patient or Participant Engagement practices
may not been investigated to identify best practices for accruing and consenting patients into clinical translational
biomedical research studies. This concept of Participant Engagement is critically important for both the patients
and the translational cancer research community. Optimizing and improving our approaches for directly
engaging patients at initial contact, throughout the course of a translational genomic study, and during the time
of return of results is likely to lead to stronger relationships between the medical community and patients, but
could also lead to significant improvement in outcomes for patients and for the cancer care community as a
whole. As such, we propose the creation of the USC Center for Optimization of Participant Engagement in
Cancer Characterization (COPECC) with a focus on optimizing the engagement of Latinos in CRC Genomic
Characterization research studies. USC COPECC would serve as a member of the NCI U2C Participant
Engagement and Cancer Genome Sequencing (PE-CGS) Network. Our investigative team includes experts in
all relevant areas of research for genomic characterization, participant engagement, and engagement
optimization. We have an established platform for consenting patients into cancer genomics studies that will
serve as a standard process. The overall goal of USC COPECC is to generate results on participant engagement
optimization and CRC genomic research that will be shared with the broader community to distribute best
practices for engaging Latinos in hopes of improving overall outcomes for CRC in this underserved population.
摘要
结直肠癌(CRC)是美国癌症死亡的第二大原因。拉美裔/拉丁裔是最大的
在美国,癌症是导致H/L死亡的首要原因。
因此,我们需要充分了解这一民族癌症分子病因学的全部复杂性。
例如,尽管与白人或非洲人相比,拉丁裔的结直肠癌发病率较低
美国人,患有转移性疾病的拉美裔人,在考虑医疗保健环境因素后,总体生存时间较短,
人口学、疾病特征和治疗因素。L也倾向于在更年轻的时候被诊断出来
并以更高的阶段,我们之前曾报道过,墨西哥H/L在加利福尼亚州拥有最大
与其他H/L亚组相比,年轻(<;50岁)诊断的比例。此外,墨西哥H/L
与其他H/L和NHW相比,直肠癌患病率更高。尽管社会经济学
而获得护理的机会可能会影响这些差异,我们需要全面了解疾病的生物学
一劳永逸地确定这些临床差异是否与分子差异有关
病因学。癌症基因组图谱提供了对594年结直肠癌分子分类的深入概述
然而,只有不到1%的病例(n=5)是H/L,因此,我们必须采取更详细的措施
H/L结直肠癌分子基因组图谱的评估可能限制我们能力的主要问题之一
在少数族裔患者中执行这些大型基因组计划的关键是患者或参与者的参与实践
可能不会被调查以确定聚集和同意患者进入临床翻译的最佳实践
生物医学研究。参与者参与度的这一概念对两个患者都至关重要
以及转化型癌症研究社区。优化和改进我们的方法,以直接
在翻译基因组研究的整个过程中,在初次接触时,以及在
结果的返回可能会导致医学界和患者之间更紧密的关系,但
还可以显著改善患者和癌症护理社区的预后
完整的。因此,我们建议成立南加州大学参与者参与度优化中心
癌症特征(COPECC),重点是优化拉丁裔在CRC基因组中的参与
表征研究研究。南加州大学COPECC将作为NCI U2C参与者的成员
参与和癌症基因组测序(PE-CGS)网络。我们的调查团队包括以下专家
基因组特征、参与者参与度和参与度的所有相关研究领域
优化。我们已经建立了一个平台,让患者同意进行癌症基因组学研究,这将
作为标准流程。南加州大学COPECC的总体目标是在参与者参与度方面产生成果
优化和CRC基因组研究,将与更广泛的社区共享以分发最佳
促进拉美裔人参与的做法,希望在这一服务不足的人口中改善儿童权利公约的总体成果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN D. CARPTEN其他文献
JOHN D. CARPTEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN D. CARPTEN', 18)}}的其他基金
USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies
USC PE-GCS:优化西班牙裔结直肠癌患者参与癌症基因组特征研究
- 批准号:
10492733 - 财政年份:2021
- 资助金额:
$ 371.25万 - 项目类别:
USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies
USC PE-GCS:优化西班牙裔结直肠癌患者参与癌症基因组特征研究
- 批准号:
10696237 - 财政年份:2021
- 资助金额:
$ 371.25万 - 项目类别:
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
非裔美国女性乳腺癌的体细胞突变及其病因决定因素
- 批准号:
10335127 - 财政年份:2019
- 资助金额:
$ 371.25万 - 项目类别:
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
非裔美国女性乳腺癌的体细胞突变及其病因决定因素
- 批准号:
10558682 - 财政年份:2019
- 资助金额:
$ 371.25万 - 项目类别:
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
非裔美国女性乳腺癌的体细胞突变及其病因决定因素
- 批准号:
10091976 - 财政年份:2019
- 资助金额:
$ 371.25万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 371.25万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 371.25万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 371.25万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 371.25万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 371.25万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 371.25万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 371.25万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 371.25万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 371.25万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 371.25万 - 项目类别: